Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen
prostate cancer patient without distant metastases with Time to Clinical progression as main
objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms
deterioration Quality of Life, PK analysis as secondary objectives